Imaging Diagnostic Systems, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private equity financing provides $25 mil. funding commitment from an institutional investor. The developer of the CTLM laser-based breast imaging device, designed to aid in the diagnosis of breast abnormalities without using breast compression or x-rays, plans to use the proceeds from the financing "for the ongoing clinical programs, product development, working capital and general corporate purposes," the firm states. The device utilizes laser technology and computed algorithms that create "contiguous cross-sectional slice images of the breast." Data from ongoing clinical trials at two sites are to be submitted to FDA in "late summer or early this fall," IDS says. The funding commitment provides the flexibility to draw upon the capital when needed, the firm notes
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.